|
Industry Sponsored Symposia Industry Sponsored Symposia (ISS) are educational programs offered during evening hours during the PAS Annual Meeting in Washington, DC. These events are not part of the official scientific sessions planned by the PAS Program Committee. The PAS Executive Committee reviewed and approved these sessions after determining the topic was timely and of broad interest to the memberships, the topic meets ACCME Guidelines and Standards for Commercial Support, and the contents are free of commercial bias for or against any product. ISS are planned solely by the sponsoring company/organization and these events are scheduled during time slots that do not compete with PAS programs or exhibit hall hours. There
is no fee to attend the PAS ISS, but pre-registration is required. The
supporting companies hosting each ISS session will send separate
invitations and registration forms and/or will have on-site registration
available at the door. Seating is available on a first-come,
first-served basis. |
|
|
Sunday,
May 15 |
Is
Prevention the Next Step for Cervical Cancer and Other Human
Papillomavirus-Related Diseases? |
|
After
attending in this activity, participants should be better able to:
Although
the clinical manifestations of human papillomavirus (HPV), genital warts
and cervical cancer, have long been characterized, the public health
burden posed by HPV is only now being fully recognized. HPV DNA testing
has revolutionized our epidemiologic estimates for prevalence,
indicating that HPV DNA is present in up to 60% of young women. Given
that HPV is implicated in the etiology of virtually every case of
cervical cancer and genital warts occurring worldwide, vaccination is
the most the most effective mechanism for prevention. This symposium
will review emerging clinical trial data regarding investigational HPV
vaccines, and will discuss the pharmacoeconomic advantages and social
barriers that will ultimately impact their acceptance and uptake into
contemporary clinical practice. Target
Audience: Pediatricians and Pediatric Infectious Disease Specialists Sponsored by Merck Vaccination Division For
additional information, contact: |
|
|
Sunday,
May 15 |
Meningococcal
Disease: New Strategies for
Disease Prevention and Treatment |
|
Niesseria
meningitidis is the leading cause of bacterial meningitis in
American children and young adults.
Since 1991, outbreaks of meningococcal disease have increased in
the United States, but represent <3% of total US cases. Rates
of meningococcal disease are highest for infants but have increased
among adolescents and young adults. During 1994-1998, about two thirds of cases in persons aged
18-23 years were caused by serogroups C, Y, or W-135 and thus were
potentially preventable. Deciding
who to target for meningococcal polysaccharide or conjugate vaccines
requires understanding of the groups at risk, the burden of disease and
the potential benefits of vaccination. Highlights
of the presentations include:
Sponsored by Sanofi Pasteur Inc. For
additional information, contact: |
|
|
Monday,
May 16
|
Ensuring
Positive Outcomes in Childhood Patient Care:
Addressing Comorbidities in ADHD |
|
This
continuing medical education activity will reveiw the pervalence of ADHD
and commonly associated comorbidities of children and adolescents
experiencing this disease. New
methods of assessing these patients will be explored in an effort to
better recommend treatment regimens.
Evidence from the Multimodal Treatment Study of Children with
ADHD (MTA) of incorporating behavioral therapies along with
pharmacological treatments in managing pediatric patients with ADHD will
be discussed. Currently
used pharmacological treatment options and their afficacy and safety
will also be reviewed. Finally,
the facutly will incorporate case studies describing how pediatric
patients present with comorbid ADHD and how to subsequently manage
sypmtoms. Sponsored by Eli Lilly and Company For
additional information, contact: |
|
|
Monday,
May 16 |
Improving
Pediatric Therapeutics Through the Best Pharmaceuticals for Children Act
of 2002 |
|
The Best Pharmaceuticals for Children Act (BPCA) was enacted into law on January 4, 2002, to address the issue of the lack of evidence-based medicine in pediatric patients. BPCA legislated that the National Institutes of Health (NIH) study on-patent and off-patent drugs in order to improve pediatric therapeutics through collaboration on scientific investigation, clinical study design, weight of evidence, and ethical and labeling issues. The Director of NIH delegated authority for establishing and conducting the pediatric drug development activity to the National Institute of Child Health and Human Development (NICHD). NICHD utilizes the off-patent written request process to review available literature or to conduct clinical studies in children for selected drugs already approved for adults. Industry sponsors are provided an opportunity to conduct the requested drug studies through issuance of a written request. If industry rejects the opportunity, the Food and Drug Administration (FDA) refers the written request to the NICHD (off-patent drugs) or the Foundation for the National Institutes of Health (FNIH, on-patent drugs). If the FNIH has sufficient funds, the drug is referred to the listing process. NICHD generally selects Pediatric Off-Patent Drug Study (PODS) Centers through a competitive procurement process that is available to the general public. Sponsored
by the National Institutes of Health, For
additional information, contact:
|
|
|
|
|